title: Differences in binding affinities of MDA, MDMA, MDEA, Amphetamine, Methamphetamine, and their deuterated analogues to solid-phase extraction cartridges.
abstract: This study evaluated the potential for partial separation of drugs from their deuterated internal standards using Cerex(®) Polycrom™ CLIN II solid-phase extraction (SPE) cartridges. After elution from the column and derivatization, gas chromatography-mass spectrometry results showed that the target compound eluted from the SPE cartridge prior to its deuterated form. This elution separation effect was greater for 3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine (MAMP) than for the other drugs studied. When the drugs were eluted in 0.5 mL increments from a 50 mg sorbent bed, no drug appeared in the first fraction. The drug to internal standard ratios (expected value 1.00) for subsequent fractions collected were 1.30, 1.07, and 0.83 for MDA/MDA-d(5); 1.65, 1.18, 0.67, and 0.56 for MDMA/MDMAd(5); and 1.37, 1.18, and 0.95 for MDEA/MDEA-d(6). For d-AMP and d-MAMP, the expected ratio was 0.40. The subsequent ratios were 0.63, 0.46, 0.35, and 0.34 for d-AMP/d-AMP-d(11); and 1.00, 0.59, 0.25, and 0.18 for d-MAMP/d-MAMP-d(14). The affinity of d-MAMPd(14) was shown to be greater than that of d-MAMP-d(5), and deuteration at the propyl end of the molecule was shown to increase binding more than deuteration on the phenyl group.
authors.affiliation: Navy Drug Screening Laboratory, 320B B Street, Great Lakes, Illinois, USA. robert.romberg@med.navy.mil
authors.forename: R W
authors.initials: RW
authors.lastname: Romberg
authors.forename: A G
authors.initials: AG
authors.lastname: Ntamack
authors.forename: L J
authors.initials: LJ
authors.lastname: Blacik
authors.forename: C M
authors.initials: CM
authors.lastname: Kazarian
authors.forename: J Jacob
authors.initials: JJ
authors.lastname: Snyder
authors.forename: E R
authors.initials: ER
authors.lastname: Welsh
mesh_terms: D015104:3,4-Methylenedioxyamphetamine / Q000031:analogs & derivatives* / Q000652:urine; D000661:Amphetamine / Q000652:urine*; D003903:Deuterium; D008401:Gas Chromatography-Mass Spectrometry; D008694:Methamphetamine / Q000031:analogs & derivatives* / Q000652:urine; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000031:analogs & derivatives* / Q000652:urine; D052616:Solid Phase Extraction; D015813:Substance Abuse Detection / Q000379:methods
chemical_list: D008694:Methamphetamine; D015104:3,4-Methylenedioxyamphetamine; D003903:Deuterium; D000661:Amphetamine; D018817:N-Methyl-3,4-methylenedioxyamphetamine; C051800:3,4-methylenedioxyethamphetamine